JP2015517529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517529A5 JP2015517529A5 JP2015512830A JP2015512830A JP2015517529A5 JP 2015517529 A5 JP2015517529 A5 JP 2015517529A5 JP 2015512830 A JP2015512830 A JP 2015512830A JP 2015512830 A JP2015512830 A JP 2015512830A JP 2015517529 A5 JP2015517529 A5 JP 2015517529A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- notch2
- antibody
- cancer
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010029751 Notch2 Receptor Proteins 0.000 claims description 112
- 102000001756 Notch2 Receptor Human genes 0.000 claims description 112
- 239000003814 drug Substances 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 229940124597 therapeutic agent Drugs 0.000 claims description 25
- 239000013612 plasmid Substances 0.000 claims description 12
- 101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 claims description 9
- 102000046883 human NOTCH2 Human genes 0.000 claims description 9
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 101000577202 Homo sapiens Neurogenic locus notch homolog protein 3 Proteins 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 238000002648 combination therapy Methods 0.000 claims description 6
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 6
- 229960005420 etoposide Drugs 0.000 claims description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 6
- 229960005277 gemcitabine Drugs 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 229940028652 abraxane Drugs 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical group 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical group C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 4
- 229960005079 pemetrexed Drugs 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 description 44
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108010029756 Notch3 Receptor Proteins 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647742P | 2012-05-16 | 2012-05-16 | |
| US61/647,742 | 2012-05-16 | ||
| US201261722340P | 2012-11-05 | 2012-11-05 | |
| US61/722,340 | 2012-11-05 | ||
| PCT/US2013/041279 WO2013173542A1 (en) | 2012-05-16 | 2013-05-16 | Methods for treating cancer with notch2/3 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015517529A JP2015517529A (ja) | 2015-06-22 |
| JP2015517529A5 true JP2015517529A5 (OSRAM) | 2016-07-07 |
Family
ID=49584275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512830A Pending JP2015517529A (ja) | 2012-05-16 | 2013-05-16 | Notch2/3抗体によって癌を治療するための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20130323266A1 (OSRAM) |
| EP (1) | EP2849785A4 (OSRAM) |
| JP (1) | JP2015517529A (OSRAM) |
| WO (1) | WO2013173542A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539403A (ja) | 2006-06-13 | 2009-11-19 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断および処置するための組成物および方法 |
| US8088617B2 (en) | 2007-01-24 | 2012-01-03 | Oncomed Pharmaceuticals, Inc. | Antibodies that bind the glutamate ligand binding region of Notch1 |
| CA2729306C (en) | 2008-07-08 | 2015-08-18 | Oncomed Pharmaceuticals, Inc. | Notch-binding agents and antagonists and methods of use thereof |
| US9132189B2 (en) | 2008-07-08 | 2015-09-15 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
| WO2014141064A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| ES2808153T3 (es) * | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| WO2017087547A1 (en) * | 2015-11-17 | 2017-05-26 | Oncomed Pharmaceuticals, Inc. | Pd-l1-binding agents and uses thereof |
| ES2931955T3 (es) * | 2016-04-29 | 2023-01-05 | Aveo Pharmaceuticals Inc | Anticuerpo anti-Notch3 |
| WO2018017827A1 (en) * | 2016-07-22 | 2018-01-25 | Fred Hutchinson Cancer Research Center | Bi-specific molecule for cell-specific notch inhibition and related methods and compositions |
| CN106800599B (zh) * | 2016-12-05 | 2021-03-23 | 中国人民解放军第二军医大学 | 抗人EGFR和Notch多特异性抗体、其制备方法及用途 |
| US11453718B2 (en) | 2017-03-27 | 2022-09-27 | The Schepens Eye Research Institute, Inc. | NOTCH3 agonist compositions and methods for treating small vessel diseases |
| WO2018183213A1 (en) | 2017-03-27 | 2018-10-04 | The Schepens Eye Research Institute, Inc. | Blood biomarkers and diagnostic methods for small vessel diseases |
| IL299799A (en) * | 2020-07-17 | 2023-03-01 | Genentech Inc | Anti-NOTCH2 antibodies and methods of use |
| CN121057747A (zh) * | 2023-04-18 | 2025-12-02 | 上海洛启生物医药技术有限公司 | 抗Notch2纳米抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009539403A (ja) * | 2006-06-13 | 2009-11-19 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 癌を診断および処置するための組成物および方法 |
| CA2729306C (en) * | 2008-07-08 | 2015-08-18 | Oncomed Pharmaceuticals, Inc. | Notch-binding agents and antagonists and methods of use thereof |
| PE20120080A1 (es) * | 2008-10-01 | 2012-02-17 | Genentech Inc | Anticuerpos anti-notch2 y metodos de uso |
| WO2012003472A1 (en) * | 2010-07-02 | 2012-01-05 | Aveo Pharmaceuticals, Inc. | Anti-notch1 antibodies |
| JP2015505668A (ja) * | 2011-11-16 | 2015-02-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヒトnotch受容体変異およびその使用 |
-
2013
- 2013-05-16 EP EP13790284.7A patent/EP2849785A4/en not_active Withdrawn
- 2013-05-16 WO PCT/US2013/041279 patent/WO2013173542A1/en not_active Ceased
- 2013-05-16 JP JP2015512830A patent/JP2015517529A/ja active Pending
- 2013-05-16 US US13/895,543 patent/US20130323266A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517529A5 (OSRAM) | ||
| WO2013173542A4 (en) | Methods for treating cancer with notch2/3 antibodies | |
| TWI596116B (zh) | 包含專一性辨識cd38之抗體及硼替佐米(bortezomib)之抗腫瘤組合 | |
| JP7092775B2 (ja) | がんを治療するための薬物の調製における、抗pd‐1抗体とvegfr阻害剤とを組み合わせた使用 | |
| JP2013520442A5 (OSRAM) | ||
| JP2016528247A5 (OSRAM) | ||
| JP6018235B2 (ja) | Cd38を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| JP2015532292A5 (OSRAM) | ||
| JP2018512435A5 (OSRAM) | ||
| JP2016502504A5 (OSRAM) | ||
| JP2016520082A5 (OSRAM) | ||
| JP2017533912A5 (OSRAM) | ||
| JP2015534578A5 (OSRAM) | ||
| JP2011046732A5 (OSRAM) | ||
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JP2015534580A5 (OSRAM) | ||
| JP2016530280A5 (OSRAM) | ||
| JP2017514795A5 (OSRAM) | ||
| JP2019506403A5 (OSRAM) | ||
| JP2014515036A5 (OSRAM) | ||
| JP2015534577A5 (OSRAM) | ||
| JP2018536624A5 (OSRAM) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2013533858A5 (OSRAM) | ||
| JP2014512356A5 (OSRAM) |